Australia's Imugene rises on fresh responses in blood cancer drug trial

Imugene

05/10/2026 05:24

** Shares of Australia's Imugene Limited IMU.AX rise as much as 35.1% to A$0.05, their highest level since September 17
** Stock on track for its biggest intraday pct rise since July 1, if current trend holds
** Clinical-stage cell therapy co reports two additional patient responses in Phase 1b trial of blood cancer therapy azer-cel
** Patient responses included one complete response in mantle cell lymphoma and one partial response in chronic lymphocytic leukemia
** All four patients had previously failed BTK inhibitor therapy - a common class of blood-cancer drug
** Says therapy has shown 75% overall response rate across 55 patients evaluated in the study
** Stock down nearly 88% YTD, including session's moves

 (Reporting by Swetha Lakshmi in Bengaluru)
 ((Swetha.Lakshmi@thomsonreuters.com))